Palvella Therapeutics, Inc. Proceeds from Sale of Productive Assets
Palvella Therapeutics, Inc. (PVLA) reported Proceeds from Sale of Productive Assets of $2.32 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2024-11-13
- Palvella Therapeutics, Inc. proceeds from sale of productive assets for the quarter ending 2024-09-30 was $142.00K.
- Palvella Therapeutics, Inc. proceeds from sale of productive assets for the quarter ending 2023-09-30 was $0.00.
| Period end | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 6 month | Proceeds from Sale of Productive Assets 9 month |
|---|---|---|---|
| 2024-09-30 | $142.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.32M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $2.18M 10-Q · filed 2024-08-14 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |